الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> GIP Receptor>>(D-Ala²)-Gastric Inhibitory Polypeptide (human)

(D-Ala²)-Gastric Inhibitory Polypeptide (human)

رقم الكتالوجGA20063

GIP receptor agonist.

Products are for research use only. Not for human use. We do not sell to patients.

(D-Ala²)-Gastric Inhibitory Polypeptide (human) التركيب الكيميائي

Cas No.: 444073-04-5

الحجم السعر المخزون الكميّة
0.5mg
239٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of (D-Ala²)-Gastric Inhibitory Polypeptide (human)

GIP receptor agonist.

Chemical Properties of (D-Ala²)-Gastric Inhibitory Polypeptide (human)

Cas No. 444073-04-5 SDF
Formula C226H338N60O66S M.Wt 4983.53
الذوبان DMSO : 50 mg/mL (10.03 mM; Need ultrasonic) Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of (D-Ala²)-Gastric Inhibitory Polypeptide (human)

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 0.2007 mL 1.0033 mL 2.0066 mL
5 mM 0.0401 mL 0.2007 mL 0.4013 mL
10 mM 0.0201 mL 0.1003 mL 0.2007 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of (D-Ala²)-Gastric Inhibitory Polypeptide (human)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for (D-Ala²)-Gastric Inhibitory Polypeptide (human)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (D-Ala²)-Gastric Inhibitory Polypeptide (human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.